Tag: Novartis
Novartis announces promising long-term data on Kesimpta for relapsing multiple sclerosis
In a significant revelation, Novartis Pharmaceuticals Corporation has announced the latest findings from the ALITHIOS open-label extension study. The data underscores the sustained efficacy of ... Read More
Novartis reports significant proteinuria reduction by Fabhalta in Phase 3 IgAN trial
Novartis has shared encouraging results from the Phase III APPLAUSE-IgAN study, revealing that Fabhalta (iptacopan) led to a significant 38.3% reduction in proteinuria, as measured ... Read More
Novartis reveals significant results for Fabhalta in IgAN study at World Congress of Nephrology
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in proteinuria in a pivotal Phase III trial. ... Read More
Novartis announces takeover bid for MorphoSys AG to boost oncology pipeline
In a significant move within the pharmaceutical industry, Novartis has entered into an agreement to launch a voluntary public takeover offer to acquire MorphoSys AG, ... Read More
Novartis’ remibrutinib shows promising results in Phase III studies for chronic spontaneous urticaria
Novartis has revealed encouraging data from the Phase III REMIX-1 and REMIX-2 studies. The studies focused on remibrutinib, a highly selective, oral Bruton’s tyrosine kinase ... Read More
FDA approves Novartis’ Cosentyx for hidradenitis suppurativa treatment
Novartis, a global leader in immuno-dermatology and rheumatology, announced the U.S. Food and Drug Administration's approval of Cosentyx (secukinumab) for treating adults with moderate to ... Read More
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
Novartis acquires kidney disease innovator Chinook Therapeutics
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper ... Read More
CHMP recommends approval for BeiGene’s tislelizumab in ESCC treatment
BeiGene, a global biotechnology firm, has revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for ... Read More
Novartis acquires biotech firm DTx Pharma to gain access to FALCON platform
Swiss pharmaceutical giant Novartis has acquired DTx Pharma, a preclinical stage biotechnology company based in California renowned for its Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) ... Read More